Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07140393 | A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor | recruiting | Phase 1 / Phase 2 | 120 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07508761 | IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 52 | Nanjing Immunophage Biotech Co., LtdINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04219254 | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 197 | BioInvent International ABINDUSTRY | 7 | Jun 25, 2026 | clinicaltrials |
| NCT07060989 | A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation(NTS071) | recruiting | Phase 1 / Phase 2 | 220 | Nutshell Therapeutics (Shanghai) Co., LTD.INDUSTRY | 2 | Jun 24, 2026 | clinicaltrials |
| NCT05584670 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | SanofiINDUSTRY | 6 | Jun 23, 2026 | clinicaltrials |
| NCT05684965 | XTX301 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 358 | Xilio Development, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06993844 | Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 233 | Ensem TherapeuticsINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT05434234 | A Study of YL201 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 312 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 6 | Jun 22, 2026 | clinicaltrials |
| NCT07208773 | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06253130 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 156 | Eikon TherapeuticsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT07019779 | Study of CM518D1 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07147348 | A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 375 | BioNTech SEINDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06630416 | Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors | recruiting | Phase 2 | 64 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04771520 | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06975410 | Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Yuhan CorporationINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07512583 | Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 178 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07570563 | Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. | recruiting | Phase 1 / Phase 2 | 24 | Chinese PLA General HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06504732 | To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer | recruiting | Phase 2 / Phase 3 | 574 | SUNHO(China)BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06554795 | First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | DualityBio Inc.INDUSTRY | 3 | Jun 5, 2026 | clinicaltrials |
| NCT05004116 | A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer | recruiting | Phase 1 / Phase 2 | 77 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04796012 | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 23 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06369831 | HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011(HERMIA) | recruiting | Phase 2 | 60 | Abscint NV/SAINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT04145622 | Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | recruiting | Phase 1 / Phase 2 | 250 | Daiichi SankyoINDUSTRY | 2 | May 29, 2026 | clinicaltrials |
| NCT06598007 | A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Crossignal Therapeutics, Inc.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07480733 | Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors | recruiting | Phase 2 | 410 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor | recruiting | Phase 1 / Phase 2 | 201 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements(TRIDENT-1) | recruiting | Phase 1 / Phase 2 | 500 | Turning Point Therapeutics, Inc.INDUSTRY | 19 | May 27, 2026 | clinicaltrials |
| NCT05384626 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | recruiting | Phase 1 / Phase 2 | 840 | Nuvalent Inc.INDUSTRY | 15 | May 27, 2026 | clinicaltrials |
| NCT05599048 | Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 65 | Robert Bok, MD, PhDOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05277168 | A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS | recruiting | Phase 1 / Phase 2 | 83 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 4 | May 22, 2026 | clinicaltrials |
| NCT06386146 | JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | recruiting | Phase 1 / Phase 2 | 144 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT06656390 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 202 | Shanghai Allink Biotherapeutics Co., Ltd.INDUSTRY | 3 | May 22, 2026 | clinicaltrials |
| NCT06953089 | DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | recruiting | Phase 2 | 450 | DualityBio Inc.INDUSTRY | 4 | May 22, 2026 | clinicaltrials |
| NCT06977737 | A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours(ATTEST) | recruiting | Phase 1 / Phase 2 | 72 | Accession Therapeutics LimitedINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT05468359 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 64 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07331155 | A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] | recruiting | Phase 2 | 110 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | May 18, 2026 | clinicaltrials |
| NCT07459998 | SKB103 for Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 277 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 18, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07589530 | Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors(SOLID-NK) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07432295 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | recruiting | Phase 2 | 180 | I-Mab Biopharma US LimitedINDUSTRY | 3 | May 14, 2026 | clinicaltrials |
| NCT03686124 | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors(ACTengine) | recruiting | Phase 1 / Phase 2 | 375 | Immatics US, Inc.INDUSTRY | 2 | May 13, 2026 | clinicaltrials |
| NCT05036226 | COAST Therapy in Advanced Solid Tumors and Prostate Cancer(COAST) | recruiting | Phase 1 / Phase 2 | 76 | Medical University of South CarolinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07390383 | A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] | recruiting | Phase 2 | 110 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT06474455 | A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 156 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 29, 2026source: clinicaltrials